Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.69 |
| ▸ | ALPI | P09923 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | XIAP | P98170 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 4/20 | 0.65 |
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | LTA4H | P09960 | 7/20 | 0.64 |
| ▸ | LAP3 | P28838 | 1/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288912 | 1.00 | SLC7A5 (0.69) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL515522 | 1.00 | SLC7A5 (0.69) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL4757532 | 0.98 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL16816702 | 0.98 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL6065556 | 0.98 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL16816706 | 0.98 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL12379285 | 0.96 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Trifluoroacetic Acid SCHEMBL8208389 | 0.93 | PTPN1 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL21340321 | 0.92 | ITGB3 (0.60) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Methyl Ester SCHEMBL28633098 | 0.91 | LTA4H (0.70) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4417221-A2 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC (US) | 2024-08-21 | — | — | EP | claimed |
| CN-115135694-B | Polymeric excipients for drug delivery applications | 廷德尔配方服务有限责任公司 | 2024-03-15 | — | — | CN | claimed |
| EP-4087543-B1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | TYNDALL FORMULATION SERVICES LLC (US) | 2024-03-06 | — | — | EP | claimed |
| US-11891482-B2 | Polymer excipients for drug delivery applications | Tyndall Formulation Services, LLC (US) | 2024-02-06 | — | — | US | claimed |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | claimed |
| CN-116730969-A | Beta-lapachone-amino acid conjugate, and preparation method and application thereof | 中国药科大学 | 2023-09-12 | — | — | CN | claimed |
| CN-116710469-A | Linear Apelin receptor agonists | 赫帕雷斯治疗有限公司 | 2023-09-05 | — | — | CN | claimed |
| EP-4225773-A1 | LINEAR APELIN RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2023-08-16 | — | — | EP | claimed |
| EP-4087543-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC (US) | 2022-11-16 | — | — | EP | claimed |
| CN-115135694-A | Polymeric excipients for drug delivery applications | 廷德尔配方服务有限责任公司 | 2022-09-30 | — | — | CN | claimed |
| US-20220251296-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC | 2022-08-11 | — | — | US | claimed |
| WO-2022079428-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | WO | claimed |
| US-11286344-B2 | Polymer excipients for drug delivery applications | Tyndall Formulation Services, LLC (US) | 2022-03-29 | — | — | US | claimed |
| WO-2021141603-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC (US) | 2021-07-15 | — | — | WO | claimed |
| US-20210214496-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC | 2021-07-15 | — | — | US | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| CN-102503850-A | Hydroxyl-contained N-acylamino acid and preparation method thereof | UNIV TIANJIN | 2012-06-20 | — | — | CN | claimed |
| US-12146004-B2 | Polymyxin compounds and uses thereof | SPERO THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4448547-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2024-10-23 | — | — | EP | disclosed |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-10-17 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| EP-4417221-A2 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-116730969-B | Beta-lapachone-amino acid conjugate, and preparation method and application thereof | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-115135694-B | Polymeric excipients for drug delivery applications | 廷德尔配方服务有限责任公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4087543-B1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | TYNDALL FORMULATION SERVICES LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11891482-B2 | Polymer excipients for drug delivery applications | Tyndall Formulation Services, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2023-12-07 | — | — | US | disclosed |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230340026-A1 | COMPOUNDS | NEW PHARMA LICENCE HOLDINGS LTD (MT) | 2023-10-26 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023108291-A9 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-09-28 | — | — | WO | disclosed |
| CN-116730969-A | Beta-lapachone-amino acid conjugate, and preparation method and application thereof | 中国药科大学 | 2023-09-12 | — | — | CN | disclosed |
| CN-116710469-A | Linear Apelin receptor agonists | 赫帕雷斯治疗有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4225773-A1 | LINEAR APELIN RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| WO-2023108291-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-4087543-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115135694-A | Polymeric excipients for drug delivery applications | 廷德尔配方服务有限责任公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220251296-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC | 2022-08-11 | — | — | US | disclosed |
| EP-3087094-B1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022079428-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| EP-3981784-A1 | REGULATORS OF CELL DIVISION | Technische Universität Dresden (DE) | 2022-04-13 | — | — | EP | disclosed |
| US-11286344-B2 | Polymer excipients for drug delivery applications | Tyndall Formulation Services, LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-11286281-B2 | Homodetic cyclic peptides targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2022-03-29 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3939989-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA 4BETA 7 INTEGRIN | Zealand Pharma A/S (DK) | 2022-01-19 | — | — | EP | disclosed |
| US-20210324007-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2021-10-21 | — | — | US | disclosed |
| EP-3387004-B1 | CYCLIC PEPTIDES TARGETING ALPHA4 BETA7 INTEGRIN | ZEALAND PHARMA AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| US-20210300932-A1 | CYCLIC PEPTIDES TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2021-09-30 | — | — | US | disclosed |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| EP-3538542-B1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA 4BETA 7 INTEGRIN | ZEALAND PHARMA AS (DK) | 2021-08-04 | — | — | EP | disclosed |
| US-11072616-B2 | Cyclic peptides targeting alpha-4-beta-7 integrin | UNIVERSITE DE MONTREAL (CA) | 2021-07-27 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021141603-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC (US) | 2021-07-15 | — | — | WO | disclosed |
| US-20210214496-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | Tyndall Formulation Services, LLC | 2021-07-15 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-10836869-B1 | Polymer excipients for drug delivery applications | Tyndall Formulation Services, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20200165300-A1 | Cyclic Peptides Targeting Alpha-4-Beta-7 Integrin | ZEALAND PHARMA A/S (DK) | 2020-05-28 | — | — | US | disclosed |
| US-20200095285-A1 | HOMODETIC CYCLIC PEPTIDES TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-03-26 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | POLYPHOR AG (CH) | 2019-04-30 | — | — | US | disclosed |
| EP-2427476-B1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-20170369523-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS THAT ARE LIGANDS FOR G-PROTEIN-COUPLED RECEPTORS (GPCRS) AND ARE MODULATORS OF TRANSCRIPTION FACTORS AND COACTIVATORS | POLYPHOR AG (CH) | 2017-12-28 | — | — | US | disclosed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160333053-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2016-11-17 | — | — | US | disclosed |
| EP-3087094-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | Polyphor AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-9284352-B2 | Beta-hairpin peptidomimetics having CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2016-03-15 | — | — | US | disclosed |
| WO-2015096873-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2015-07-02 | — | — | WO | disclosed |
| US-20140364583-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2014-12-11 | — | — | US | disclosed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | disclosed |
| US-8865656-B2 | Beta-hairpin peptidomimetics having CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8841291-B2 | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| CN-102503850-B | Hydroxyl-contained N-acylamino acid and preparation method thereof | UNIV TIANJIN | 2014-06-11 | — | — | CN | disclosed |
| US-8716242-B2 | β-hairpin peptidomimetics | POLYPHOR AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2014-01-30 | — | — | US | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20120283196-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | disclosed |
| CN-102503850-A | Hydroxyl-contained N-acylamino acid and preparation method thereof | UNIV TIANJIN | 2012-06-20 | — | — | CN | disclosed |
| US-20120135942-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2012-05-31 | — | — | US | disclosed |
| WO-2012051663-A1 | ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2012-04-26 | — | — | WO | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-20110230426-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2011-09-22 | — | — | US | disclosed |
| WO-2011066869-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| EP-2324047-A2 | TEMPLATE-FIXED PEPTIDOMIMETICS | Polyphor Ag (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-2318361-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010107832-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010015287-A2 | TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010007027-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| CN-101443349-A | Compounds and compositions as channel activating protease inhibitors | IRM LLC (VG) | 2009-05-27 | — | — | CN | disclosed |
| EP-2027143-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008010238-A2 | ANTIDIABETIC AZABICYCLO [3. 1. 0] HEXAN COMPOUNDS | LUPIN LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008010238-A2 | ANTIDIABETIC AZABICYCLO [3. 1. 0] HEXAN COMPOUNDS | LUPIN LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| EP-1636164-A2 | PROCESS FOR PREPARING 3-ARYL-2-HYDROXY PROPANOIC ACID DERIVATIVES WITHOUT RESOLUTION | CADILA HEALTHCARE LTD. (IN) | 2006-03-22 | — | — | EP | disclosed |
| US-20050137408-A1 | Process for producing aminoepoxide | AJINOMOTO CO. INC (JP) | 2005-06-23 | — | — | US | disclosed |
| WO-2005019152-A2 | PROCESS FOR PREPARING 3-ARYL-2-HYDROXY PROPANOIC ACID DERIVATIVES WITHOUT RESOLUTION | CADILA HEALTHCARE LIMITED (IN) | 2005-03-03 | — | — | WO | disclosed |
| EP-1505065-A1 | PROCESS FOR PRODUCING AMINOEPOXIDE | Ajinomoto Co., Inc. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-0008494-B1 | METHOD OF IMPROVING OR MAINTAINING DIGESTIBILITY OF FODDER CROPS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-22 | — | — | EP | disclosed |
| US-4304592-A | Method of improving or maintaining digestibility of fodder crops | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-12-08 | — | — | US | disclosed |
| EP-0008494-A1 | Method of improving or maintaining digestibility of fodder crops | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-03-05 | — | — | EP | disclosed |
| US-4043993-A | New pentapeptides and methods for their production | PARKE, DAVIS & COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
| US-4043993-A | New pentapeptides and methods for their production | PARKE, DAVIS & COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (39 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135942-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | CXCR4, CXCL12, CXCR6 | SLC7A5 1427/4885ALPI 4711/4885PKM 2768/4885 |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885ALPI 3773/4885PKM 3794/4885 |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC7A5 1600/4885ALPI 2014/4885PKM 2553/4885 |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | SLC7A5 2832/4885ALPI 4284/4885PKM 4395/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | SLC7A5 2832/4885ALPI 4284/4885PKM 4395/4885 |
| US-11286344-B2 | Polymer excipients for drug delivery applications | CLTB, ACTB, TNNC1 | SLC7A5 20/4885ALPI 1545/4885PKM 272/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | SLC7A5 2832/4885ALPI 4284/4885PKM 4395/4885 |
| US-11286281-B2 | Homodetic cyclic peptides targeting alpha-4-beta-7 integrin | ITGB4, ITGB7, ITGA4 | SLC7A5 2439/4885ALPI 3802/4885PKM 4305/4885 |
| US-20160333053-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | SERPINB1, ELANE, XPNPEP1 | SLC7A5 1527/4885ALPI 4162/4885PKM 3920/4885 |
| US-20200095285-A1 | HOMODETIC CYCLIC PEPTIDES TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB4, ITGB7, ITGA4 | SLC7A5 2439/4885ALPI 3802/4885PKM 4305/4885 |
| US-20120283196-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | CXCL12, CXCR4, CXCR1 | SLC7A5 1496/4885ALPI 4237/4885PKM 2243/4885 |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | APLNR, AP3D1, AP3B1 | SLC7A5 495/4885ALPI 110/4885PKM 2004/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | SLC7A5 2832/4885ALPI 4284/4885PKM 4395/4885 |
| US-20220251296-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | CLTB, ACTB, TNNC1 | SLC7A5 20/4885ALPI 1545/4885PKM 272/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2076/4885ALPI 3864/4885PKM 3336/4885 |
| US-20230340026-A1 | COMPOUNDS | BCAT1, BCAT2, CCNT1 | SLC7A5 360/4885ALPI 2894/4885PKM 2959/4885 |
| US-20210300932-A1 | CYCLIC PEPTIDES TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC7A5 1511/4885ALPI 4715/4885PKM 4465/4885 |
| US-11891482-B2 | Polymer excipients for drug delivery applications | CLTB, ACTB, TNNC1 | SLC7A5 20/4885ALPI 1545/4885PKM 272/4885 |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | SLC7A5 2374/4885ALPI 218/4885PKM 1602/4885 |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | SERPINB1, ELANE, XPNPEP1 | SLC7A5 1527/4885ALPI 4162/4885PKM 3920/4885 |
| US-20110230426-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS | STAT6, NCOA1, UTS2R | SLC7A5 3911/4885ALPI 2591/4885PKM 2794/4885 |
| US-20200165300-A1 | Cyclic Peptides Targeting Alpha-4-Beta-7 Integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 1511/4885ALPI 4715/4885PKM 4465/4885 |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | SLC7A5 4343/4885ALPI 3334/4885PKM 4421/4885 |
| US-20050137408-A1 | Process for producing aminoepoxide | HAO2, DAO, HAAO | SLC7A5 1199/4885ALPI 2741/4885PKM 3374/4885 |
| US-12146004-B2 | Polymyxin compounds and uses thereof | BCAT1, BCAT2, PNISR | SLC7A5 477/4885ALPI 3861/4885PKM 1995/4885 |
| US-20210214496-A1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | CLTB, ACTB, TNNC1 | SLC7A5 20/4885ALPI 1545/4885PKM 272/4885 |
| US-10836869-B1 | Polymer excipients for drug delivery applications | CLTB, ACTB, TNNC1 | SLC7A5 20/4885ALPI 1545/4885PKM 272/4885 |
| US-20170369523-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS THAT ARE LIGANDS FOR G-PROTEIN-COUPLED RECEPTORS (GPCRS) AND ARE MODULATORS OF TRANSCRIPTION FACTORS AND COACTIVATORS | NCOA1, NCOA2, NCOR1 | SLC7A5 4428/4885ALPI 3896/4885PKM 3883/4885 |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885ALPI 3773/4885PKM 3794/4885 |
| US-11072616-B2 | Cyclic peptides targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 1511/4885ALPI 4715/4885PKM 4465/4885 |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | LHCGR, GNRHR, FSHR | SLC7A5 3395/4885ALPI 2692/4885PKM 1851/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885ALPI 3773/4885PKM 3794/4885 |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | SLC7A5 2212/4885ALPI 202/4885PKM 1521/4885 |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | PCNA, BOD1L1, MKI67 | SLC7A5 3835/4885ALPI 3834/4885PKM 2618/4885 |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | APLNR, MTNR1A, EDNRA | SLC7A5 2228/4885ALPI 2143/4885PKM 4557/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2493/4885ALPI 3753/4885PKM 3560/4885 |
| US-20210324007-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC7A5 2591/4885ALPI 3867/4885PKM 3790/4885 |
| US-20140364583-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | CXCR4, CXCL12, CXCR1 | SLC7A5 981/4885ALPI 4771/4885PKM 3154/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | SLC7A5 4343/4885ALPI 3334/4885PKM 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.